Search

Displaying results 6551 - 6560 of 6949 in total
  1. Drug

    Cantuzumab ravtansine

    go.drugbank.com/drugs/DB05594
    Investigational

  2. Drug

    OTI-030

    go.drugbank.com/drugs/DB05648
    Investigational

  3. Drug

    Iodofiltic acid I-123

    go.drugbank.com/drugs/DB05683
    Investigational

  4. Drug

    MVA-BN-HER-2

    go.drugbank.com/drugs/DB05733
    Experimental

  5. Drug

    AGS-005

    go.drugbank.com/drugs/DB05741
    Experimental

    AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.

  6. Drug

    Tasquinimod

    go.drugbank.com/drugs/DB05861
    Investigational

    The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

  7. Drug

    MBT-0312

    go.drugbank.com/drugs/DB05880
    Experimental

    MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.

  8. Drug

    NV-18

    go.drugbank.com/drugs/DB05886
    Experimental

    NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all hu...

  9. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

  10. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1).